We maintain our Neutral recommendation for
). The company reported third quarter adjusted earnings per share
of $4.46 surpassing the Zacks Consensus Estimate of $3.48.
Intuitive stated revenues of $537.8 million, up about 20% year
over year, beating the Zacks Consensus Estimate of $535 million.
Revenues from instruments and accessories were $218 million in
the third quarter, up 24% year over year. Procedure growth was
about 22% in the third quarter. The rise in general and
gynecological procedures in the domestic market was partly offset
by reduced growth in Europe and a fall in prostatectomy
procedures in the U.S.
Systems revenues came in at $232 million in the third quarter, up
17% year over year. The growth was driven by higher sales of da
Vinci systems. Intuitive noted that 155 da Vinci Surgical Systems
were sold in the quarter, compared with 133 systems in the
Service revenues rose 22% year over year to $88 million, aided by
an increase in the installed base of da Vinci systems.
For 2012, revenues are forecast to grow in the range of 21.5% to
23% compared with the earlier guidance of 20% to 23%. Operating
income is expected at about 40% compared to approximately 39% to
40% of net sales earlier. The company updated its procedure
growth at 24% (earlier in the band of 25% and 27%) for 2012.
We expect a number of procedures that are currently completed
either in an open surgical manner or with laparoscopy to be
eventually replaced by da Vinci surgery, as robotic surgery
becomes the standard of care in many instances. The company
enjoys a virtual monopoly in robotic surgery with little
Intuitive's recurring revenue stream continues to be robust and
provides a shield against cyclicality of revenues arising from
the sale of discretionary capital equipment to hospitals.
However, we believe that until the global economy fully recovers,
the stock may come under pressure as investors ponder whether
lingering macro economic uncertainty weakens hospitals'
commitment towards investment in high-cost robotic systems.
The pace of adoption of robotic surgery may therefore be lumpy
and growth in usage requires acceptance from patients and
training for medical practitioners. Intuitive competes with
) in certain niches.
We prefer to remain on the sidelines partly due to high
valuation, which factors in the attractive growth prospects of
the company, despite the da Vinci system's status as a leading
enabler of robotic minimally invasive surgery. Our Neutral
recommendation is supported by a short-term Zacks #3 Rank (Hold).
ACCURAY INC (ARAY): Free Stock Analysis
INTUITIVE SURG (ISRG): Free Stock Analysis
To read this article on Zacks.com click here.